Agios Pharmaceuticals (AGIO) EBITDA Margin (2012 - 2026)
Agios Pharmaceuticals (AGIO) reported EBITDA Margin of 530.34% for Q1 2026, up 69163.0% on a YoY basis from N/an in Q1 2025, and up 12.9% quarter-over-quarter from 608.89% in Q4 2025.
Agios Pharmaceuticals (AGIO) EBITDA Margin (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals has reported EBITDA Margin for 14 years, with the latest figure at 530.34% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 69163.0% year-over-year to 530.34%; the trailing twelve-month figure through Mar 2026 stood at 719.97% (up 46889.0% YoY), and the FY2025 full-year result was 873.87%, up 29260.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 530.34%, up from 608.89% in the prior quarter.
- The five-year high for EBITDA Margin was 530.34% in Q1 2026, with the low at 12156.85% in Q1 2022.
- Historically, EBITDA Margin has averaged 1977.81% across 5 years, with a median of 1228.29% in 2024.
- Annual changes were most pronounced in 2023 — EBITDA Margin surged 1054136 bps — and 2025, when it plunged 9763 bps.
- Agios Pharmaceuticals' EBITDA Margin stood at 2300.97% in 2022, then soared by 35 bps to 1496.23% in 2023, then advanced by 22 bps to 1165.3% in 2024, then jumped by 48 bps to 608.89% in 2025, then rose by 13 bps to 530.34% in 2026.
- The last three EBITDA Margin figures came in at 530.34% (Q1 2026), 608.89% (Q4 2025), and 907.37% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Agios Pharmaceuticals | 2.01 Bn | 2.01 Bn | 19.43 Mn | -530.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -530.34% |
| Dec 31, 2025 | -608.89% |
| Sep 30, 2025 | -907.37% |
| Jun 30, 2025 | -1,020.12% |
| Mar 31, 2025 | -1,221.97% |
| Dec 31, 2024 | -1,165.30% |
| Sep 30, 2024 | -1,146.93% |
| Jun 30, 2024 | -1,228.29% |
| Mar 31, 2024 | -1,124.34% |
| Dec 31, 2023 | -1,496.23% |
| Sep 30, 2023 | -1,363.66% |
| Jun 30, 2023 | -1,396.01% |
| Mar 31, 2023 | -1,615.49% |
| Dec 31, 2022 | -2,300.97% |
| Sep 30, 2022 | -2,590.73% |
| Jun 30, 2022 | -1,749.19% |
| Mar 31, 2022 | -12,156.85% |
| Dec 31, 2020 | -209.86% |
| Sep 30, 2020 | -288.00% |
| Jun 30, 2020 | -238.08% |